Steven Ingel, most recently from DJO, LLC (now Enovis™) is the new president and CEO of Precision Medical Products, Inc., a medical device company based in Carrollton, Texas.
Steven Ingel Is Precision Medical’s New President and CEO
2 min read Premium comments
Secondary#precisionmedicalproducts#steveningel
Ingel is 30-year veteran of the healthcare industry and joins Precision Medical Products from Dallas, Texas-based DJO, LLC (now Enovis™). Over a period of 28 years, Ingel built his career at DJO where he progressed from national and regional sales manager positions to various executive leadership positions.
He most recently assumed the role of president of Footcare Solutions and National Accounts for Enovis (formerly DJO Global). Prior to that, Ingel spent five years as executive vice president of DJO Healthcare Solutions.
In his newest role Ingel is succeeding Precision Medical Products’ current president and CEO, Jeremy Perkins. Perkins will stay on with Precision Medical Products as chairman of the board of directors and continue to play an important role including “identifing strategies, business opportunities, and new technology architectures to grow Precision Medical Products.”
According to Perkins, “Steve Ingel brings a wealth of medical device and digital health experience with a well-established proven track record of driving growth, margin expansion, and overall financial performance.”
Perkins continued, “His broad and deep industry experience combined with his respected leadership and team-building style make him the right fit to continue our important work at Precision Medical.”
Founded in 2010, Precision Medical Products specializes in solutions for postoperative recovery. The company is known for its deep vein thrombosis (DVT) and bracing solutions and, per its website, “founded mobile DVT compression.”
Ingel told OTW that he was “looking forward to establishing Precision Medical as an Orthopedic destination company while further enabling its already explosive growth.” For the remainder of this year, he hopes to “continue to focus the company on delivering best in class innovation and service in the DVT space to the benefit of patients and providers.”
“I am honored to have the opportunity to lead Precision Medical and to begin working with its outstanding leadership team and talented organization of professionals.”
Ingel continued, “There are tremendous opportunities ahead given the company’s existing technologies, robust pipeline, and manufacturing platforms, and I’m looking forward to leading its next stage of growth. Together with Jeremy [Perkins] and the team, I am confident that we can continue to set the standards for excellence and drive innovation in the industry for our customers, patients, and employees.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.